for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca Says Farxiga Showed Cardiovascular And Renal Benefit In Patients With Chronic Kidney Disease Irrespective Of Cardiovascular Disease Status

Nov 13 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA - FARXIGA SHOWED CARDIOVASCULAR AND RENAL BENEFIT IN PATIENTS WITH CHRONIC KIDNEY DISEASE IRRESPECTIVE OF CARDIOVASCULAR DISEASE STATUS

* ASTRAZENECA - SAFETY AND TOLERABILITY OF FARXIGA (DAPAGLIFLOZIN) WERE CONSISTENT WITH THE WELL-ESTABLISHED SAFETY PROFILE OF THE MEDICINE Source text: bit.ly/3nkdENu Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up